Knowledge & Resources

Swissmedic has performed inspections at class 1 manufacturers

Swissmedic has performed inspections at class 1 manufacturers within Switzerland. The result is impressive, but not surprising due to our experience as Authorised Representative in EU, Switzerland and UK. During our onboarding process EUMEDIQ, we check not only completeness of Technical Documentation of our customer, we also do a plausibility check in order to estimate […]

Swissmedic has performed inspections at class 1 manufacturers Read More »

Cybersecurity for Medical Device Manufacturers in EU

In December 2022, the European Commission published the new directive (EU) 2022/2555 on measures for a common level of cybersecurity across the Union. This led to the amendment of the regulation (EU) 910/2014 on electronic identification and trust services for electronic transactions in the internal market (also known as eIDAS regulation) and repeals the NIS

Cybersecurity for Medical Device Manufacturers in EU Read More »

BREAKING NEWS – EUMEDIQ Ltd. has opened its office in London!

BREAKING NEWS – EUMEDIQ Ltd. has opened its office in London! EUMEDIQ is now providing UK, EU and Swiss Authorised Representative Services next to Consulting (MDR, IVDR, GDPR and ISO 27001 and ISO 13485) and Auditing Services. Further benefits: More wins with maximum efficiency Your qualified partner to reach your target markets High degree of automation and

BREAKING NEWS – EUMEDIQ Ltd. has opened its office in London! Read More »

Why regulatory strategy is essential for startup managers

Medical device startups are mainly combining latest technologies (i.e., interconnectivity of medical devices, software and machine learning diagnosis with the help of Big Data). In doing so they demand highly skilled resources in each field of it. EUMEDIQ is often asked by startups for support in regulatory consulting during design & development stages. The experience

Why regulatory strategy is essential for startup managers Read More »

The MDR approach on substances which are carcinogenic, mutagenic or toxic to reproduction (‘CMR’)

One of the big changes in EU MDR 2017/745 in contrast to the MDD are the clear requirements on the handling of substances which are carcinogenic, mutagenic or toxic to reproduction (‘CMR’). Fortunately, manufacturers are not meant to define by themselves which substances are considered CMR. REGULATION (EC) No 1272/2008, Annex VI, part 3 provides

The MDR approach on substances which are carcinogenic, mutagenic or toxic to reproduction (‘CMR’) Read More »